Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Trial ID or NCT#
NCT00519662
Status
NOT RECRUITING
Purpose
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
Official Title
Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Advanced solid tumor and that is measurable by a scan
Exclusion Criteria:
- * Uncontrolled or untreated central nervous system metastases* Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1* Any of the following cardiac conditions:* History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle 1 Day 1* Class III or IV heart failure up to 6 months before Cycle 1 Day 1* Baseline heart rate corrected QT interval (QTc)\> 450 msec* History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1* Use of medications that prolong the QTc interval and are associated with Torsades de Pointe (TdP)* Previous cancer treatment up to 21 days before first dose* Any investigational therapy up to 28 days before Cycle 1 Day 1* Known allergy to cyclodextrins
- Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.
Investigator(s)
Ranjana Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Contact us to find out if this trial is right for you.
Contact
Sipra Choudhury
6507362563
View on ClinicalTrials.gov
